27259326|t|Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients
27259326|a|Hepatocellular carcinoma (HCC) is one of the most aggressive tumors in humans. T lymphocytes and natural killer (NK) cells are the body's first line of defense to prevent tumor cell growth. Previous studies have demonstrated that transcatheter arterial chemoembolization (TACE) combined with argon-helium cryosurgery system (AHCS) can effectively treat liver cancer. However, the mechanism of the treatment is unclear yet. In the current study, we investigated the effects of TACE combined with AHCS on the changes of T cell subsets and NK cells in peripheral blood of HCC. Our data show that alpha-fetoprotein (AFP) levels in peripheral blood were significantly up-regulated in HCC patients before treatment when compared with healthy people and reduced after TACE combined with AHCS treatment (P < 0.01). In addition, we found that CD4+ cells and NK cells decreased (P < 0.05) and CD8+ cells increased (P < 0.05) in HCC patients when compared with healthy people. After treatment, the CD4+ cells, CD4+ / CD8+ ratio, and NK cells were dramatically increased in HCC patients (P < 0.05). In contrast, CD8+ cells were significantly decreased (P < 0.05). TACE combined with AHCS treatment significantly prolonged 1- year survival rate of HCC patients and did not show significant side effects. Taken together, our data indicate that TACE combined with AHCS treatment improves patients ' immune system. It is a feasible and effective therapeutic method for HCC patients.
27259326	10	50	Transcatheter Arterial Chemoembolization	T058	UMLS:C3888803
27259326	65	96	Argon-Helium Cryosurgery System	T058	UMLS:C0010408
27259326	115	123	NK Cells	T017	UMLS:C0022688
27259326	128	142	T Cell Subsets	T017	UMLS:C0080202
27259326	146	162	Peripheral Blood	T031	UMLS:C0229664
27259326	166	190	Hepatocellular Carcinoma	T038	UMLS:C2239176
27259326	200	224	Hepatocellular carcinoma	T038	UMLS:C2239176
27259326	226	229	HCC	T038	UMLS:C2239176
27259326	261	267	tumors	T038	UMLS:C0027651
27259326	271	277	humans	T204	UMLS:C0086418
27259326	279	292	T lymphocytes	T017	UMLS:C0039194
27259326	317	322	cells	T017	UMLS:C0007634
27259326	331	337	body's	T204	UMLS:C0242821
27259326	352	359	defense	T038	UMLS:C0520990
27259326	371	381	tumor cell	T017	UMLS:C0597032
27259326	382	388	growth	T038	UMLS:C0007595
27259326	390	406	Previous studies	T062	UMLS:C2603343
27259326	430	470	transcatheter arterial chemoembolization	T058	UMLS:C3888803
27259326	472	476	TACE	T058	UMLS:C3888803
27259326	492	523	argon-helium cryosurgery system	T058	UMLS:C0010408
27259326	525	529	AHCS	T058	UMLS:C0010408
27259326	525	529	AHCS	T058	UMLS:C0010408
27259326	547	552	treat	T058	UMLS:C0087111
27259326	553	565	liver cancer	T038	UMLS:C0345904
27259326	597	606	treatment	T058	UMLS:C0087111
27259326	638	643	study	T062	UMLS:C2603343
27259326	676	680	TACE	T058	UMLS:C3888803
27259326	695	699	AHCS	T058	UMLS:C0010408
27259326	718	732	T cell subsets	T017	UMLS:C0080202
27259326	737	745	NK cells	T017	UMLS:C0022688
27259326	749	765	peripheral blood	T031	UMLS:C0229664
27259326	769	772	HCC	T038	UMLS:C2239176
27259326	793	810	alpha-fetoprotein	T103	UMLS:C0002210
27259326	812	815	AFP	T103	UMLS:C0002210
27259326	827	843	peripheral blood	T031	UMLS:C0229664
27259326	863	875	up-regulated	T038	UMLS:C0041904
27259326	879	882	HCC	T038	UMLS:C2239176
27259326	899	908	treatment	T058	UMLS:C0087111
27259326	936	942	people	T098	UMLS:C0027361
27259326	961	965	TACE	T058	UMLS:C3888803
27259326	980	984	AHCS	T058	UMLS:C0010408
27259326	985	994	treatment	T058	UMLS:C0087111
27259326	1034	1044	CD4+ cells	T017	UMLS:C0039215
27259326	1049	1057	NK cells	T017	UMLS:C0022688
27259326	1083	1093	CD8+ cells	T017	UMLS:C0242629
27259326	1118	1121	HCC	T038	UMLS:C2239176
27259326	1158	1164	people	T098	UMLS:C0027361
27259326	1172	1181	treatment	T058	UMLS:C0087111
27259326	1187	1197	CD4+ cells	T017	UMLS:C0039215
27259326	1199	1203	CD4+	T017	UMLS:C0039215
27259326	1206	1210	CD8+	T017	UMLS:C0242629
27259326	1222	1230	NK cells	T017	UMLS:C0022688
27259326	1262	1265	HCC	T038	UMLS:C2239176
27259326	1300	1310	CD8+ cells	T017	UMLS:C0242629
27259326	1352	1356	TACE	T058	UMLS:C3888803
27259326	1371	1375	AHCS	T058	UMLS:C0010408
27259326	1376	1385	treatment	T058	UMLS:C0087111
27259326	1435	1438	HCC	T038	UMLS:C2239176
27259326	1477	1489	side effects	T038	UMLS:C0879626
27259326	1530	1534	TACE	T058	UMLS:C3888803
27259326	1549	1553	AHCS	T058	UMLS:C0010408
27259326	1554	1563	treatment	T058	UMLS:C0087111
27259326	1564	1572	improves	T033	UMLS:C0184511
27259326	1584	1597	immune system	T022	UMLS:C0020962
27259326	1630	1648	therapeutic method	T058	UMLS:C0087111
27259326	1653	1656	HCC	T038	UMLS:C2239176